Morgan Stanley Madrigal Pharmaceuticals, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Morgan Stanley holds 269,394 shares of MDGL stock, worth $84.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

269,394

Previous 220,031 22.43%

Holding current value

$84.6 Million

Previous $61.6 Million 7.26%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$212.22 - $292.96 $10.5 Million - $14.5 Million	49,363 Added 22.43%	269,394 $57.2 Million
Q2 2024 Oct 17, 2024	SELL	$193.33 - $291.99 $13.3 Million - $20 Million	-68,575 Reduced 23.76%	220,031 $61.6 Million
Q2 2024 Aug 14, 2024	SELL	$193.33 - $291.99 $13.3 Million - $20 Million	-68,575 Reduced 23.76%	220,031 $61.6 Million
Q1 2024 Oct 17, 2024	BUY	$171.37 - $283.23 $11.8 Million - $19.4 Million	68,575 Added 31.17%	288,606 $77.1 Million
Q1 2024 Aug 16, 2024	BUY	$171.37 - $283.23 $23.4 Million - $38.7 Million	136,688 Added 89.97%	288,606 $77.1 Million
Q1 2024 May 15, 2024	BUY	$171.37 - $283.23 $23.4 Million - $38.7 Million	136,688 Added 89.97%	288,606 $77.1 Million
Q4 2023 Aug 16, 2024	SELL	$120.4 - $237.13 $8.2 Million - $16.2 Million	-68,113 Reduced 30.96%	151,918 $35.2 Million
Q4 2023 Feb 13, 2024	SELL	$120.4 - $237.13 $2.39 Million - $4.71 Million	-19,855 Reduced 11.56%	151,918 $35.2 Million
Q3 2023 Nov 15, 2023	BUY	$146.04 - $225.78 $14.2 Million - $22 Million	97,480 Added 131.21%	171,773 $25.1 Million
Q2 2023 Aug 14, 2023	SELL	$203.88 - $312.0 $15 Million - $22.9 Million	-73,486 Reduced 49.73%	74,293 $17.2 Million
Q1 2023 May 15, 2023	BUY	$231.06 - $307.08 $8.86 Million - $11.8 Million	38,359 Added 35.06%	147,779 $35.8 Million
Q4 2022 Feb 14, 2023	BUY	$58.39 - $296.54 $2.94 Million - $14.9 Million	50,356 Added 85.26%	109,420 $31.8 Million
Q3 2022 Nov 14, 2022	SELL	$60.57 - $79.51 $1.45 Million - $1.9 Million	-23,889 Reduced 28.8%	59,064 $3.84 Million
Q2 2022 Oct 27, 2022	SELL	$58.04 - $100.2 $874,720 - $1.51 Million	-15,071 Reduced 15.37%	82,953 $5.94 Million
Q2 2022 Aug 15, 2022	SELL	$58.04 - $100.2 $874,720 - $1.51 Million	-15,071 Reduced 15.37%	82,953 $5.94 Million
Q1 2022 Oct 27, 2022	BUY	$55.89 - $101.89 $842,318 - $1.54 Million	15,071 Added 18.17%	98,024 $9.62 Million
Q1 2022 May 13, 2022	BUY	$55.89 - $101.89 $2.78 Million - $5.06 Million	49,686 Added 102.79%	98,024 $9.62 Million
Q4 2021 Feb 14, 2022	SELL	$72.34 - $95.09 $1.43 Million - $1.89 Million	-19,830 Reduced 29.09%	48,338 $4.1 Million
Q3 2021 Nov 15, 2021	BUY	$78.35 - $105.02 $5.34 Million - $7.16 Million	68,168 New	68,168 $5.44 Million

Others Institutions Holding MDGL

# of Institutions

297

Shares Held

22M

Call Options Held

819K

Put Options Held

640K

View Full List

About MADRIGAL PHARMACEUTICALS, INC.

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.37B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

More about MDGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account